ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The company is headquartered in Winston-Salem, North Carolina and currently employs 204 full-time employees. The company went IPO on 2021-06-30. The firm is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, rilparencel, is designed to preserve kidney function in a CKD patient’s diseased kidneys. Rilparencel is a product that includes autologous selected renal cells (SRCs) prepared from a patient’s own (autologous) kidney cells. Rilparencel is an investigational product that includes a mixture of kidney cells prepared from the participant’s own kidney tissue. The SRC are formulated rilparencel for reinjection into the patient’s kidneys using a minimally invasive outpatient procedure that is repeatable, if necessary. The company is conducting a global Phase III development program and multiple Phase II clinical trials for rilparencel in subjects with moderate to severe CKD and diabetes.
Follow-Up Questions
ProKidney Corp 的 CEO 是誰？
Dr. Bruce Culleton 是 ProKidney Corp 的 Chief Executive Officer，自 2023 加入公司。
PROK 股票的價格表現如何？
PROK 的當前價格為 $2.71，在上個交易日 increased 了 0.18%。
ProKidney Corp 的主要業務主題或行業是什麼？
ProKidney Corp 屬於 Biotechnology 行業，該板塊是 Health Care
